Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are established therapies for diabetes and obesity, heart transplant recipients have been excluded from pivotal trials due to concerns regarding gastrointestinal intolerance, altered drug absorption, and possible interactions with immunosuppressants. Here, GLP1R is linked to Obesity.